Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2019
At a glance
- Drugs Antisense K-ras RNA gene therapy (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PROTACT
- Sponsors Silenseed
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2019.
- 14 Nov 2017 Planned initiation date changed from 1 Feb 2017 to 1 Nov 2017.